A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
- Wagner, AJ
- Kindler, H
- Gelderblom, H
- Schöffski, Patrick
- Bauer, S
- Hohenberger, P
- Kopp, H-G
- Lopez-Martin, JA
- Peeters, M
- Reichardt, P
- Qin, A
- Nippgen, J
- Ilaria, RL
- Rutkowski, P
Publication date
March 2017
DOI Publisher
Oxford University Press (OUP) Journal
Annals of OncologyAbstract
This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively).status: publishe
Add to ORKG